Biomarkers and Disease Severity in Children With Community-Acquired Pneumonia
- 1 June 2020
- journal article
- research article
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 145 (6)
- https://doi.org/10.1542/peds.2019-3728
Abstract
BACKGROUND: Host biomarkers predict disease severity in adults with community-acquired pneumonia (CAP). We evaluated the association of the white blood cell (WBC) count, absolute neutrophil count (ANC), C-reactive protein (CRP), and procalcitonin with the development of severe outcomes in children with CAP. METHODS: We performed a prospective cohort study of children 3 months to 18 years of age with CAP in the emergency department. The primary outcome was disease severity: mild (discharged from the hospital), mild-moderate (hospitalized but not moderate-severe or severe), moderate-severe (eg, hospitalized with receipt of intravenous fluids, supplemental oxygen, complicated pneumonia), and severe (eg, intensive care, vasoactive infusions, chest drainage, severe sepsis). Outcomes were examined within the cohort with suspected CAP and in a subset with radiographic CAP. RESULTS: Of 477 children, there were no statistical differences in the median WBC count, ANC, CRP, or procalcitonin across severity categories. No biomarker had adequate discriminatory ability between severe and nonsevere disease (area under the curve [AUC]: 0.53–0.6 for suspected CAP and 0.59–0.64 for radiographic CAP). In analyses adjusted for age, antibiotic use, fever duration, and viral pathogen detection, CRP was associated with moderate-severe disease (odds ratio 1.12; 95% confidence interval, 1.0–1.25). CRP and procalcitonin revealed good discrimination of children with empyema requiring chest drainage (AUC: 0.83) and sepsis with vasoactive infusions (CRP AUC: 0.74; procalcitonin AUC: 0.78), although prevalence of these outcomes was low. CONCLUSIONS: WBC count, ANC, CRP, and procalcitonin are generally not useful to discriminate nonsevere from severe disease in children with CAP, although CRP and procalcitonin may have some utility in predicting the most severe outcomes.This publication has 31 references indexed in Scilit:
- Usefulness of consecutive biomarkers measurement in the management of community-acquired pneumoniaEuropean Journal of Clinical Microbiology & Infectious Diseases, 2011
- Prediction of Pneumonia in a Pediatric Emergency DepartmentPediatrics, 2011
- Utility of C-reactive protein in assessing the disease severity and complications of community-acquired pneumoniaClinical Microbiology & Infection, 2009
- Inflammatory parameters predict etiologic patterns but do not allow for individual prediction of etiology in patients with CAP – Results from the German competence network CAPNETZRespiratory Research, 2009
- Risk Prediction With Procalcitonin and Clinical Rules in Community-Acquired PneumoniaAnnals of Emergency Medicine, 2008
- Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 classesEuropean Respiratory Journal, 2007
- Development of parapneumonic empyema in childrenActa Paediatrica, 2007
- Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumoniaBMC Infectious Diseases, 2007
- Efficacy of serum procalcitonin in evaluating severity of community-acquired pneumonia in childhoodScandinavian Journal of Infectious Diseases, 2007
- Estimation of Average Concentration in the Presence of Nondetectable ValuesApplied Occupational and Environmental Hygiene, 1990